With the latest version of Genedata Screener, we achieve a major step forward in our goal for full end-to-end lab automation and AI-supported decision-making. Othmar Pfannes, Ph.D., CEO at Genedata
BASEL, Switzerland (PRWEB) February 21, 2023
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the release of Genedata Screener® 20. The most comprehensive digital platform for assay analysis in Biopharma R&D, Genedata Screener shortens design-make-test-analyze (DMTA) cycles in R&D through real-time data capture and automated analysis of simple and complex assays. It consolidates and FAIRifies assay information across the enterprise, including with CROs and other external collaborators. Genedata Screener provides easy access to fully integrated, up-to-date assay information to global R&D teams, providing significant time savings, and enabling efficient decision-making.
The new Genedata Screener 20 will be featured among SLAS2023 Tutorial Sessions and demonstrated at SLAS Booth #1044 (February 25 – March 1; San Diego Convention Center).
Automated Data Workflows Enable End-to-End Lab Automation
“Many companies are investing in laboratory automation to scale up and accelerate their research and development workflows. Genedata Screener tremendously increases the ROI of those investments by automating the corresponding data workflows,” noted Othmar Pfannes, Ph.D., CEO of Genedata. “Genedata Screener intelligently captures and integrates experimental data directly from a variety of analytical instruments, ensuring that only data of the highest quality enters the automated data analysis workflows. Moreover, it enables the contextualization of ontology-based annotations for guided decision-making and real-time publication of results,” continued Dr. Pfannes. “With the latest version of Genedata Screener, we achieve a major step forward in our goal for full end-to-end lab automation and AI-supported decision-making. Genedata Screener should enable biopharma R&D organizations to develop innovative biotherapeutics faster and more efficiently.”
Genedata Screener digitalizes assay workflows and integrates and condenses complex experimental data to power efficient project decisions. Some of the advanced new capabilities of Genedata Screener version 20 include:
- Turn-key autonomous data loading and real-time analysis to accelerate the DMTA cycle in drug discovery and reduce consumable spend by alerts on experiments going the wrong way.
- FAIRification of Assay data by establishing an Assay Catalog that integrates controlled vocabularies from internal and external providers. The FAIR data concept included in Genedata Screener lays a solid foundation for cross-site collaboration, data transparency, as well as AI-based predictions and project decisions.
- Automated data capture from assay runs to ingest assay results simply and systematically. The Result Uploader module captures assays from internal and external sites such as CROs and other collaborators, adds relevant metadata, and enables their review and publishing by internal project teams.
- Mass Spectrometry Screening Extension enables broad adoption of mass spectrometry screening in mid- to high-throughput with ready-to-go analysis workflows. The extension covers widely-used assay formats such as Affinity Selection, Multiple Reaction Monitoring, and a range of Covalent Binding assays.
Genedata Screener Tutorials at SLAS2023
Genedata will demonstrate Genedata Screener 20’s newest capabilities at SLAS2023 Booth #1044. Additionally, the Genedata team, along with our partners at Biosero and AstraZeneca, will present the following tutorials:
Monday, February 27 | 2:00 pm – 3:00 pm
Fill the Discovery Funnel with Quality Hits Using Label-Free, Multiplexed Mass-Spectrometry and Safety Assays with the Genedata Screener Analysis Platform
Matthias Fassler, Head of Product Management, Genedata
Tuesday, February 28 | 9:00 am – 10:00 am
It’s Time to Think About Automating Data Processes the Way We Automate Wet Lab Processes
Rachel Moore, Senior Research Scientist, AstraZeneca
Guy Williams, Senior Research Scientist, AstraZeneca
Jesse Mayer, Applications Consulting Manager, Biosero
Sascha Fischer, Business Development Manager, Genedata
Editorial Note: To schedule a SLAS2023 briefing or one-on-one demonstration of Genedata Screener 20, email firstname.lastname@example.org.
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.